• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Develops API Production and Supply Information Collection Platform

NMPA Develops API Production and Supply Information Collection Platform

Tuesday, 23 November 2021 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

NMPA Develops API Production and Supply Information Collection Platform

In order to strengthen the supervision and management of APIs and to clarify the production and supply of APIs, the NMPA announced (No.96-2021) the development of an API production and supply information collection module in the drug information collection platform on November 3, 2021.

In an effort to steadily promote the use of this new module and to implement this new management work step by step, starting from the third quarter of 2021, the production and supply information of APIs for all drugs which have been included in the “National Scarce Drug List” and “National Key Monitoring List for Clinically Essential and Scarce drugs” must be collected through this new module. Depending on the needs of drug regulatory work, the NMPA will subsequently expand the scope of the information collection and include other API varieties into this project. At this stage, manufacturers of other API varieties can also voluntarily take part in this project.

Domestic API manufacturers should provide the production and supply information through this API production and supply information collection module and submit it online to the provincial drug supervision and management department.

If the manufacturer is an overseas enterprise, it should appoint a legal agent in China to submit the required information online to the local department of the province where the legal agent is located. The manufacturer and legal agent are responsible for the accuracy, comprehensiveness and completeness of the information provided. The collected API production and supply information can be used by drug regulatory authorities for inquiries.

The relevant API manufacturers should submit the API production and supply information by the end of November 2021. After that, they should do this before the 20th of the first month of each quarter for the previous quarter.

By Sun Jinlin. Contact Cisema if you would like to learn more.

What you can read next

Reformation for Production Licenses and SAMR announces Brake Pad Products for CCC Certification
Important amendment to China’s Pressure Vessel Directive (China Manufacturer License, CML)
Webinar China Cosmetics
Webinar: China Cosmetics Ingredient Code Submission

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.